|
|
 |
|
Viewing report
|
|
|
|
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Bioseeker, July 2011, Pages: 1,323
This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. BioSeeker has applied its unique drug assessment methodology to stratify the lung cancer pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of lung cancer drugs is split between the 43% which have unique drug target strategies and the other part which have head-to-head target competing lung cancer drugs in 58 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lung cancer drugs in general. Contributing to this fact is heavily utilized drug target strategies like: TUBB, TOP2A and TOP1.
- Nine out of ten drug target strategies in Phase II development are new to lung cancer drugs and the greatest numbers of new target strategies are found in Phase II (39%) and Phase I development (17%).
- Small molecules, antibodies and reformulated drugs are the dominating compound strategies of lung cancer drugs, which represent almost 80% of the entire pipeline. Cell therapy based lung cancer drugs has the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lung cancer drugs.
- Peptide based lung cancer drugs has a 50% drug target strategy overlap with all other compound strategies, especially with that of antibodies, small molecules and reformulated compound strategies.
- The highest number of described drug target strategies of lung cancer drugs belongs to Pfizer (15), Bristol-Myers Squibb (11) and Hoffmann-La Roche (11).
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lung cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.
|
|
|
|
